Characterization and burden of severe eosinophilic asthma in New Zealand: Results from the HealthStat Database
Keywords:
Severe eosinophilic asthma, New Zealand, epidemiology, costsAbstract
Background: This retrospective cohort study aimed to characterize epidemiology, medication use and healthcare resource utilization (HCRU) of patients diagnosed with severe eosinophilic asthma (SEA) compared to other patients with asthma in New Zealand.
Methods: Adult patients with asthma with no concurrent diagnosis of Chronic Obstructive Lung Disease (COPD) were identified from the HealthStat primary care database and the National Minimum Dataset using asthma diagnosis, hospital codes and prescriptions. Patients with SEA were identified using a 1-year baseline period (2011) and were those with: inhaled corticosteroid prescription above medium dose (including high dose) plus controller medication, ≥2 exacerbations, and eosinophils ≥300 cells/µl (or ≥150 in 6 weeks prior to index date); patients were followed for 1 year (2012).
Results: 160/3276 (4.9%) asthmatics with available eosinophil counts met SEA criteria. Patients with SEA were more likely to be Māori, former smokers, have more comorbidities, higher mean BMI and higher neutrophil counts compared with other patients with asthma. In the follow-up period, SEA patients had over 4 times as many exacerbations; incidence of exacerbations of the same frequency were highest in Māori patients.
Conclusions: Compared with other patients with asthma, SEA patients had over 1.5 times as many respiratory treatment prescriptions and higher all-cause HCRU and total healthcare costs; asthma-related healthcare costs were 3.6 times greater.
References
Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-373.
Calhoun WJ, Haselkorn T, Mink DR, et al. Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort. J Allergy Clin Immunol Pract 2014;2:193-200.
Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322-6.
Dean BB, Calimlim BC, Sacco P, et al. Uncontrolled asthma: assessing quality of life and productivity of children and their caregivers using a cross-sectional Internet-based survey. Health Qual Life Outcomes 2010;8:96.
Fleming L, Murray C, Bansal AT, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J 2015;46:1322.
Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015;46:1308-1321.
Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009;9:24-24.
Barnard L, Baker M, Pierse N, et al. The impact of respiratory disease in New Zealand: 2014 update. 2015. Last accessed: February 2019. Available from: www.asthmafoundation.org.nz/research/the-impact-of-respiratory-disease-in-new-zealand-2014-update
Lai CK, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009;64:476-83.
Crane J, Lewis S, Slater T, et al. The self reported prevalence of asthma symptoms amongst adult New Zealanders. N Z Med J 1994;107:417-21.
Ellison-Loschmann L, Pattemore PK, Asher MI, et al. Ethnic differences in time trends in asthma prevalence in New Zealand: ISAAC Phases I and III. Int J Tuberc Lung Dis 2009;13:775-82.
Pattemore PK, Ellison-Loschmann L, Asher MI, et al. Asthma prevalence in European, Maori, and Pacific children in New Zealand: ISAAC study. Pediatr Pulmonol 2004;37:433-42.
Gillies TD, Tomlin AM, Dovey SM, et al. Ethnic disparities in asthma treatment and outcomes in children aged under 15 years in New Zealand: analysis of national databases. Prim Care Respir J 2013;22:312-8.
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Last accessed: February 2019. Available from: https://www.ucalgary.ca/icancontrolasthma/files/icancontrolasthma/wms-gina-2016-main-report-final.pdf
Shantakumar S, Yu-Fan H, Beale J, et al. An observational study to characterize severe eosinophilic asthma in New Zealand. Eur Respir J 2018;52:PA1155.
Respiratory Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC). Mepolizumab for severe eosinophilic asthma - minutes of the 2017 PTAC meeting. Last accessed: October 2019. Available from: https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2017-08.pdf
Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax 2018;73:116-24.
Shantakumar S, Yu-Fan H, Li-Wen T, et al. A retrospective observational study to characterize severe eosinophilic asthma in Taiwan. Eur Respir J 2018;52:PA3917. doi: 10.1183/13993003.congress-2018.PA3917
Lang JE, Hossain J, Smith K, et al. Asthma severity, exacerbation risk, and controller treatment burden in underweight and obese children. J Asthma 2012;49:456-63.
Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 2012;185:356-62.
de Carvalho-Pinto RM, Cukier A, Angelini L, et al. Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med 2012;106:47-56.
Barnard L, Zhang J. The impact of respiratory disease in New Zealand: 2018 update. Last accessed: April 2019. Available from: https://s3-ap-southeast-2.amazonaws.com/assets.asthmafoundation.org.nz/images/NZ-Impact-Report-2018_FINAL.pdf
New Zealand Ministry of Health. Tatau Kahukura Māori Health Chart Book 2010. Wellington: Ministry of Health, 2010.
Lewis S, Hales S, Slater T, et al. Geographical variation in the prevalence of asthma symptoms in New Zealand. N Z Med J 1997;110:286-9.
New Zealand Ministry of Health. Ngā mana hauora tūtohu: Health status indicators - Asthma. 2018. Last accessed: March 2019. Available from: https://www.health.govt.nz/our-work/populations/maori-health/tatau-kahukura-maori-health-statistics/nga-mana-hauora-tutohu-health-status-indicators/respiratory-disease.
Robson B, Harris R. Hauora: Māori Standards of Health IV. A study of the years 2000–2005. Wellington: Te Ropu Rangahau Hauora a Eru Pomare; 2007.
Beasley R, Hancox RJ, Harwood M, et al. Asthma and Respiratory Foundation NZ adult asthma guidelines: a quick reference guide. N Z Med J 2016;129:83-102.
New Zealand Ministry of Health. Neighbourhood deprivation. 2013. Last accessed: April 2019. Available from: https://www.health.govt.nz/our-work/populations/maori-health/tatau-kahukura-maori-health-statistics/nga-awe-o-te-hauora-socioeconomic-determinants-health/neighbourhood-deprivation
Poyser MA, Nelson H, Ehrlich RI, et al. Socioeconomic deprivation and asthma prevalence and severity in young adolescents. Eur Respir J 2002;19:892.
Downloads
Published
Issue
Section
License
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
